Resveratrol, a phytochemical inducer of multiple cell death pathways: Apoptosis, autophagy and mitotic catastrophe

Current Medicinal Chemistry

Volumn 18, Issue 8, 2011, Pages 1100-1121

  Delmas, D ^a,b   Solary, E ^a,b   Latruffe, N ^a,b  

^a Chu   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

Apoptosis; Cancer; Chemosensitization; Lipid rafts; Phagocytosis; Resveratrol

Indexed keywords

BORTEZOMIB; CAPSAICIN; CARBOPLATIN; CERAMIDE; CYCLOPHOSPHAMIDE; CYTARABINE; DEATH RECEPTOR; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; HS 1793; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METHOTREXATE; NAVELBINE; PACLITAXEL; PHENOL DERIVATIVE; PROTEIN BCL 2; PROTEIN KINASE C; PROTEIN P53; REACTIVE OXYGEN METABOLITE; RESVERATROL; RESVERATROL DERIVATIVE; ROSCOVITINE; SPHINGOMYELIN; THALIDOMIDE; TIAZOFURIN; UNCLASSIFIED DRUG; VINCRISTINE;

ACYLATION; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER RESISTANCE; CELL CYCLE ARREST; CHEMOSENSITIZATION; COLORECTAL CANCER; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG STRUCTURE; DRUG SULFATION; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION REGULATION; GROWTH INHIBITION; HUMAN; IONIZING RADIATION; ISOMERIZATION; LIPID RAFT; MEMBRANE DEPOLARIZATION; MEMBRANE PERMEABILITY; METHYLATION; MITOCHONDRIAL ENERGY TRANSFER; MITOSIS INHIBITION; OXIDATIVE PHOSPHORYLATION; PROTEIN EXPRESSION; RESPIRATORY CHAIN; SENESCENCE; TRANSACTIVATION; TUMOR REGRESSION;

ANIMALS; APOPTOSIS; AUTOPHAGY; HUMANS; MITOSIS; PHYTOTHERAPY; STILBENES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79952801721     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986711795029708     Document Type: Article

References (308)

1. Reed, J.C. Mechanisms of apoptosis avoidance in cancer. Curr. Opin. Oncol., 1999, 11, 68-75. (Pubitemid 29082059)
2. Hanahan, D. and Weinberg, R.A. The hallmarks of cancer. Cell, 2000, 100, 57-70. (Pubitemid 30046295)
3. Delmas, D.; Lancon, A.; Colin, D.; Jannin, B. and Latruffe, N. Resveratrol as a chemopreventive agent: A promising molecule for fighting cancer. Curr. Drug Targets, 2006, 7, 423-442. (Pubitemid 43744833)
4. Athar, M.; Back, J.H.; Kopelovich, L.; Bickers, D.R. and Kim, A.L. Multiple molecular targets of resveratrol: Anti-carcinogenic mechanisms. Arch. Biochem. Biophys., 2009, 486, 95-102.
5. Shakibaei, M.; Harikumar, K.B. and Aggarwal, B.B. Resveratrol addiction: To die or not to die. Mol. Nutr. Food. Res., 2009, 53, 115-128.
6. Jang, M.; Cai, L.; Udeani, G.O.; Slowing, K.V.; Thomas, C.F.; Beecher, C.W.; Fong, H.H.; Farnsworth, N.R.; Kinghorn, A.D.; Mehta, R.G.; Moon, R.C. and Pezzuto, J.M. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science, 1997, 275, 218-220. (Pubitemid 127696281)
7. Kraft, T.E.; Parisotto, D.; Schempp, C. and Efferth, T. Fighting cancer with red wine? Molecular mechanisms of resveratrol. Crit. Rev. Food. Sci. Nutr., 2009, 49, 782-799.
8. Susin, S.A.; Lorenzo, H.K.; Zamzami, N.; Marzo, I.; Snow, B.E.; Brothers, G.M.; Mangion, J.; Jacotot, E.; Costantini, P.; Loeffler, M.; Larochette, N.; Goodlett, D.R.; Aebersold, R.; Siderovski, D.P.; Penninger, J.M. and Kroemer, G. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature, 1999, 397, 441-446.
9. Mancini, M.; Nicholson, D.W.; Roy, S.; Thornberry, N.A.; Peterson, E.P.; Casciola-Rosen, L.A. and Rosen, A. The caspase-3 precursor has a cytosolic and mitochondrial distribution: Implications for apoptotic signaling. J. Cell. Biol., 1998, 140, 1485-1495. (Pubitemid 28152996)
10. Green, D.R. and Reed, J.C. Mitochondria and apoptosis. Science, 1998, 281, 1309-1312. (Pubitemid 28406816)
11. Pedersen, P.L. and Amzel, L.M. ATP synthases. Structure, reaction center, mechanism, and regulation of one of nature's most unique machines. J. Biol. Chem., 1993, 268, 9937-9940. (Pubitemid 23150162)
12. Boyer, P.D. The ATP synthase-a splendid molecular machine. Annu. Rev. Biochem., 1997, 66, 717-749. (Pubitemid 27274672)
13. Fang, N. and Casida, J.E. Anticancer action of cube insecticide: Correlation for rotenoid constituents between inhibition of NADH:ubiquinone oxidoreductase and induced ornithine decarboxylase activities. Proc. Natl. Acad. Sci. U.S.A., 1998, 95, 3380-3384. (Pubitemid 28173136)
14. Zheng, J. and Ramirez, V.D. Inhibition of mitochondrial proton F0F1- ATPase/ATP synthase by polyphenolic phytochemicals. Br. J. Pharmacol., 2000, 130, 1115-1123. (Pubitemid 30453547)
15. Zheng, J. and Ramirez, V.D. Piceatannol, a stilbene phytochemical, inhibits mitochondrial F0F1-ATPase activity by targeting the F1 complex. Biochem. Biophys. Res. Commun., 1999, 261, 499-503. (Pubitemid 29392505)
16. Arakaki, N.; Nagao, T.; Niki, R.; Toyofuku, A.; Tanaka, H.; Kuramoto, Y.; Emoto, Y.; Shibata, H.; Magota, K. and Higuti, T. Possible role of cell surface H+ -ATP synthase in the extracellular ATP synthesis and proliferation of human umbilical vein endothelial cells. Mol. Cancer Res., 2003, 1, 931-939. (Pubitemid 37463349)
17. Gledhill, J.R. and Walker, J.E. Inhibition sites in F1-ATPase from bovine heart mitochondria. Biochem. J., 2005, 386, 591-598. (Pubitemid 40445885)
18. van Raaij, M.J.; Abrahams, J.P.; Leslie, A.G. and Walker, J.E. The structure of bovine F1-ATPase complexed with the antibiotic inhibitor aurovertin B. Proc. Natl. Acad. Sci. U.S.A., 1996, 93, 6913-6917. (Pubitemid 26243474)
19. Gledhill, J.R.; Montgomery, M.G.; Leslie, A.G. and Walker, J.E. Mechanism of inhibition of bovine F1-ATPase by resveratrol and related polyphenols. Proc. Natl. Acad. Sci. U.S.A., 2007, 104, 13632-13637. (Pubitemid 350003372)
20. Vayssiere, J.L.; Petit, P.X.; Risler, Y. and Mignotte, B. Commitment to apoptosis is associated with changes in mitochondrial biogenesis and activity in cell lines conditionally immortalized with simian virus 40. Proc. Natl. Acad. Sci. U.S.A., 1994, 91, 11752-11756. (Pubitemid 24356423)
21. Zamzami, N.; Marchetti, P.; Castedo, M.; Zanin, C.; Vayssiere, J.L.; Petit, P.X. and Kroemer, G. Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J. Exp. Med., 1995, 181, 1661-1672.
22. Wallace, D.C. Mitochondrial diseases in man and mouse. Science, 1999, 283, 1482-1488.
23. Mignotte, B. and Vayssiere, J.L. Mitochondria and apoptosis. Eur. J. Biochem., 1998, 252, 1-15. (Pubitemid 28089952)
24. Boveris, A.; Cadenas, E. and Stoppani, A.O. Role of ubiquinone in the mitochondrial generation of hydrogen peroxide. Biochem. J., 1976, 156, 435-444.
25. Zini, R.; Morin, C.; Bertelli, A.; Bertelli, A.A. and Tillement, J.P. Effects of resveratrol on the rat brain respiratory chain. Drugs Exp. Clin. Res., 1999, 25, 87-97. (Pubitemid 29257599)
26. Morin, C.; Zini, R.; Albengres, E.; Bertelli, A.A.; Bertelli, A. and Tillement, J.P. Evidence for resveratrol-induced preservation of brain mitochondria functions after hypoxia-reoxygenation. Drugs Exp. Clin. Res., 2003, 29, 227-233. (Pubitemid 38568629)
27. Yen, G.C.; Duh, P.D. and Lin, C.W. Effects of resveratrol and 4- hexylresorcinol on hydrogen peroxide-induced oxidative DNA damage in human lymphocytes. Free Radic. Res., 2003, 37, 509-514.
28. Kampa, M.; Hatzoglou, A.; Notas, G.; Damianaki, A.; Bakogeorgou, E.; Gemetzi, C.; Kouroumalis, E.; Martin, P.M. and Castanas, E. Wine antioxidant polyphenols inhibit the proliferation of human prostate cancer cell lines. Nutr. Cancer, 2000, 37, 223-233.
29. Sainz, R.M.; Mayo, J.C.; Tan, D.X.; Lopez-Burillo, S.; Natarajan, M. and Reiter, R.J. Antioxidant activity of melatonin in Chinese hamster ovarian cells: Changes in cellular proliferation and differentiation. Biochem. Biophys. Res. Commun., 2003, 302, 625-634. (Pubitemid 36279577)
30. Lopez-Burillo, S.; Tan, D.X.; Mayo, J.C.; Sainz, R.M.; Manchester, L.C. and Reiter, R.J. Melatonin, xanthurenic acid, resveratrol, EGCG, vitamin C and alpha-lipoic acid differentially reduce oxidative DNA damage induced by Fenton reagents: A study of their individual and synergistic actions. J. Pineal. Res., 2003, 34, 269-277. (Pubitemid 36469773)
31. Kasdallah-Grissa, A.; Mornagui, B.; Aouani, E.; Hammami, M.; El May, M.; Gharbi, N.; Kamoun, A. and El-Fazaa, S. Resveratrol, a red wine polyphenol, attenuates ethanol-induced oxidative stress in rat liver. Life Sci., 2006.
32. Hu, Y.; Rahlfs, S.; Mersch-Sundermann, V. and Becker, K. Resveratrol modulates mRNA transcripts of genes related to redox metabolism and cell proliferation in non-small-cell lung carcinoma cells. Biol. Chem., 2007, 388, 207-219. (Pubitemid 46184150)
33. Sengottuvelan, M.; Deeptha, K. and Nalini, N. Resveratrol ameliorates DNA damage, prooxidant and antioxidant imbalance in 1,2-dimethylhydrazine induced rat colon carcinogenesis. Chem. Biol. Interact., 2009, 181, 193-201.
34. Sengottuvelan, M.; Senthilkumar, R. and Nalini, N. Modulatory influence of dietary resveratrol during different phases of 1,2-dimethylhydrazine induced mucosal lipid-peroxidation, antioxidant status and aberrant crypt foci development in rat colon carcinogenesis. Biochim. Biophys. Acta, 2006, 1760, 1175-1183. (Pubitemid 43928257)
35. Sener, G.; Topaloglu, N.; Ozer Sehirli, A.; Ercan, F. and Gedik, N. Resveratrol alleviates bleomycin-induced lung injury in rats. Pulm. Pharmacol. Ther., 2006.
36. Clement, M.V.; Hirpara, J.L.; Chawdhury, S.H. and Pervaiz, S. Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. Blood, 1998, 92, 996-1002. (Pubitemid 28355484)
37. Lee, S.C.; Chan, J.; Clement, M.V. and Pervaiz, S. Functional proteomics of resveratrol-induced colon cancer cell apoptosis: Caspase-6-mediated cleavage of lamin A is a major signaling loop. Proteomics, 2006, 6, 2386-2394.
38. Ahmad, K.A.; Clement, M.V.; Hanif, I.M. and Pervaiz, S. Resveratrol inhibits drug-induced apoptosis in human leukemia cells by creating an intracellular milieu nonpermissive for death execution. Cancer Res., 2004, 64, 1452-1459. (Pubitemid 38235616)
39. Kroemer, G. and Reed, J.C. Mitochondrial control of cell death. Nat. Med., 2000, 6, 513-519. (Pubitemid 30305900)
40. Antonsson, B.; Conti, F.; Ciavatta, A.; Montessuit, S.; Lewis, S.; Martinou, I.; Bernasconi, L.; Bernard, A.; Mermod, J.J.; Mazzei, G.; Maundrell, K.; Gambale, F.; Sadoul, R. and Martinou, J.C. Inhibition of Bax channelforming activity by Bcl-2. Science, 1997, 277, 370-372. (Pubitemid 27450709)
41. Crompton, M. The mitochondrial permeability transition pore and its role in cell death. Biochem. J., 1999, 341, 233-249. (Pubitemid 29373645)
42. Marzo, I.; Brenner, C.; Zamzami, N.; Jurgensmeier, J.M.; Susin, S.A.; Vieira, H.L.; Prevost, M.C.; Xie, Z.; Matsuyama, S.; Reed, J.C. and Kroemer, G. Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. Science, 1998, 281, 2027-2031. (Pubitemid 28475490)
43. Hu, Y.; Benedict, M.A.; Ding, L. and Nunez, G. Role of cytochrome c and dATP/ATP hydrolysis in Apaf-1-mediated caspase-9 activation and apoptosis. EMBO J., 1999, 18, 3586-3595. (Pubitemid 29308839)
44. Liu, X.; Kim, C.N.; Yang, J.; Jemmerson, R. and Wang, X. Induction of apoptotic program in cell-free extracts: Requirement for dATP and cytochrome c. Cell, 1996, 86, 147-157. (Pubitemid 26256586)
45. Bernardi, P.; Colonna, R.; Costantini, P.; Eriksson, O.; Fontaine, E.; Ichas, F.; Massari, S.; Nicolli, A.; Petronilli, V. and Scorrano, L. The mitochondrial permeability transition. Biofactors, 1998, 8, 273-281. (Pubitemid 29021358)
46. Tinhofer, I.; Bernhard, D.; Senfter, M.; Anether, G.; Loeffler, M.; Kroemer, G.; Kofler, R.; Csordas, A. and Greil, R. Resveratrol, a tumor-suppressive compound from grapes, induces apoptosis via a novel mitochondrial pathway controlled by Bcl-2. FASEB J., 2001, 15, 1613-1615.
47. Zunino, S.J. and Storms, D.H. Resveratrol-induced apoptosis is enhanced in acute lymphoblastic leukemia cells by modulation of the mitochondrial permeability transition pore. Cancer Lett., 2006, 240, 123-134. (Pubitemid 44037172)
48. Sareen, D.; Darjatmoko, S.R.; Albert, D.M. and Polans, A.S. Mitochondria, calcium, and calpain are key mediators of resveratrol-induced apoptosis in breast cancer. Mol. Pharmacol., 2007, 72, 1466-1475. (Pubitemid 350146084)
49. Tian, X.M.; Ma, X.D. and Yan, F. [Resveratrol promotes Ca2+-induced Ca2+ release from rat liver cell mitochondria mediated by Ca2+]. Nan. Fang. Yi. Ke. Da. Xue. Xue. Bao, 2006, 26, 910-913.
50. Ma, X.; Tian, X.; Huang, X.; Yan, F. and Qiao, D. Resveratrol-induced mitochondrial dysfunction and apoptosis are associated with Ca(2+) and mCICR-mediated MPT activation in HepG2 cells. Mol. Cell. Biochem., 2007.
51. Tian, X.M. and Zhang, Z.X. [Resveratrol promote permeability transition pore opening mediated by Ca2+]. Yao. Xue. Xue. Bao, 2003, 38, 81-84.
52. Devarajan, E.; Sahin, A.A.; Chen, J.S.; Krishnamurthy, R.R.; Aggarwal, N.; Brun, A.M.; Sapino, A.; Zhang, F.; Sharma, D.; Yang, X.H.; Tora, A.D. and Mehta, K. Down-regulation of caspase 3 in breast cancer: A possible mechanism for chemoresistance. Oncogene, 2002, 21, 8843-8851. (Pubitemid 36132404)
53. Solary, E.; Bettaieb, A.; Dubrez-Daloz, L. and Corcos, L. Mitochondria as a target for inducing death of malignant hematopoietic cells. Leuk. Lymphoma, 2003, 44, 563-574. (Pubitemid 36304813)
54. Nakagawa, H.; Kiyozuka, Y.; Uemura, Y.; Senzaki, H.; Shikata, N.; Hioki, K. and Tsubura, A. Resveratrol inhibits human breast cancer cell growth and may mitigate the effect of linoleic acid, a potent breast cancer cell stimulator. J. Cancer Res. Clin. Oncol., 2001, 127, 258-264.
55. Aziz, M.H.; Nihal, M.; Fu, V.X.; Jarrard, D.F. and Ahmad, N. Resveratrolcaused apoptosis of human prostate carcinoma LNCaP cells is mediated via modulation of phosphatidylinositol 3'-kinase/Akt pathway and Bcl-2 family proteins. Mol. Cancer Ther., 2006, 5, 1335-1341. (Pubitemid 43881327)
56. Kim, Y.A.; Choi, B.T.; Lee, Y.T.; Park, D.I.; Rhee, S.H.; Park, K.Y.; Choi, Y.H. Resveratrol inhibits cell proliferation and induces apoptosis of human breast carcinoma MCF-7 cells. Oncol. Rep., 2004, 11, 441-446.
57. Hsieh, T.C.; Burfeind, P.; Laud, K.; Backer, J.M.; Traganos, F.; Darzynkiewicz, Z. and Wu, J.M. Cell cycle effects and control of gene expression by resveratrol in human breast carcinoma cell lines with different metastatic potentials. Int. J. Oncol., 1999, 15, 245-252.
58. Surh, Y.J.; Hurh, Y.J.; Kang, J.Y.; Lee, E.; Kong, G. and Lee, S.J. Resveratrol, an antioxidant present in red wine, induces apoptosis in human promyelocytic leukemia (HL-60) cells. Cancer Lett., 1999, 140, 1-10. (Pubitemid 29251307)
59. Roman, V.; Billard, C.; Kern, C.; Ferry-Dumazet, H.; Izard, J.C.; Mohammad, R.; Mossalayi, D.M. and Kolb, J.P. Analysis of resveratrol-induced apoptosis in human B-cell chronic leukaemia. Br. J. Haematol., 2002, 117, 842-851. (Pubitemid 34639245)
60. Billard, C.; Izard, J.C.; Roman, V.; Kern, C.; Mathiot, C.; Mentz, F. and Kolb, J.P. Comparative antiproliferative and apoptotic effects of resveratrol, epsilon-viniferin and vine-shots derived polyphenols (vineatrols) on chronic B lymphocytic leukemia cells and normal human lymphocytes. Leuk. Lymphoma, 2002, 43, 1991-2002.
61. Sun, C.; Hu, Y.; Liu, X.; Wu, T.; Wang, Y.; He, W. and Wei, W. Resveratrol downregulates the constitutional activation of nuclear factor-kappaB in multiple myeloma cells, leading to suppression of proliferation and invasion, arrest of cell cycle, and induction of apoptosis. Cancer Genet. Cytogenet., 2006, 165, 9-19. (Pubitemid 43254647)
62. Pozo-Guisado, E.; Merino, J.M.; Mulero-Navarro, S.; Lorenzo-Benayas, M.J.; Centeno, F.; Alvarez-Barrientos, A. and Salguero, P.M. Resveratrolinduced apoptosis in MCF-7 human breast cancer cells involves a caspaseindependent mechanism with downregulation of Bcl-2 and NF-kappaB. Int. J. Cancer, 2005, 115, 74-84. (Pubitemid 40559670)
63. Bishayee, A. and Dhir, N. Resveratrol-mediated chemoprevention of diethylnitrosamine- initiated hepatocarcinogenesis: Inhibition of cell proliferation and induction of apoptosis. Chem. Biol. Interact., 2009, 179, 131-144.
64. Kalra, N.; Roy, P.; Prasad, S. and Shukla, Y. Resveratrol induces apoptosis involving mitochondrial pathways in mouse skin tumorigenesis. Life Sci., 2007.
65. Shankar, S.; Chen, Q.; Siddiqui, I.; Sarva, K. and Srivastava, R.K. Sensitization of TRAIL-resistant LNCaP cells by resveratrol (3, 4', 5 trihydroxystilbene): Molecular mechanisms and therapeutic potential. J. Mol. Signal., 2007, 2, 7.
66. Bhardwaj, A.; Sethi, G.; Vadhan-Raj, S.; Bueso-Ramos, C.; Takada, Y.; Gaur, U.; Nair, A.S.; Shishodia, S. and Aggarwal, B.B. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood, 2007, 109, 2293-2302. (Pubitemid 46425866)
67. Zhou, H.B.; Chen, J.J.; Wang, W.X.; Cai, J.T. and Du, Q. Anticancer activity of resveratrol on implanted human primary gastric carcinoma cells in nude mice. World J. Gastroenterol., 2005, 11, 280-284. (Pubitemid 40125220)
68. Della Ragione, F.; Cucciolla, V.; Criniti, V.; Indaco, S.; Borriello, A. and Zappia, V. Antioxidants induce different phenotypes by a distinct modulation of signal transduction. FEBS Lett., 2002, 532, 289-294. (Pubitemid 35441363)
69. Delmas, D.; Rebe, C.; Lacour, S.; Filomenko, R.; Athias, A.; Gambert, P.; Cherkaoui-Malki, M.; Jannin, B.; Dubrez-Daloz, L.; Latruffe, N. and Solary, E. Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells. J. Biol. Chem., 2003, 278, 41482-41490. (Pubitemid 37280977)
70. Kim, Y.A.; Lee, W.H.; Choi, T.H.; Rhee, S.H.; Park, K.Y. and Choi, Y.H. Involvement of p21WAF1/CIP1, pRB, Bax and NF-kappaB in induction of growth arrest and apoptosis by resveratrol in human lung carcinoma A549 cells. Int. J. Oncol., 2003, 23, 1143-1149.
71. Jazirehi, A.R. and Bonavida, B. Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Mol. Cancer Ther., 2004, 3, 71-84. (Pubitemid 39193680)
72. Kotha, A.; Sekharam, M.; Cilenti, L.; Siddiquee, K.; Khaled, A.; Zervos, A.S.; Carter, B.; Turkson, J. and Jove, R. Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol. Cancer Ther., 2006, 5, 621-629.
73. Zhou, H.B.; Yan, Y.; Sun, Y.N. and Zhu, J.R. Resveratrol induces apoptosis in human esophageal carcinoma cells. World J. Gastroenterol., 2003, 9, 408-411. (Pubitemid 36372096)
74. Kaneuchi, M.; Sasaki, M.; Tanaka, Y.; Yamamoto, R.; Sakuragi, N. and Dahiya, R. Resveratrol suppresses growth of Ishikawa cells through downregulation of EGF. Int. J. Oncol., 2003, 23, 1167-1172.
75. Park, J.W.; Choi, Y.J.; Suh, S.I.; Baek, W.K.; Suh, M.H.; Jin, I.N.; Min, D.S.; Woo, J.H.; Chang, J.S.; Passaniti, A.; Lee, Y.H. and Kwon, T.K. Bcl-2 overexpression attenuates resveratrol-induced apoptosis in U937 cells by inhibition of caspase-3 activity. Carcinogenesis, 2001, 22, 1633-1639. (Pubitemid 32952140)
76. Haldar, S.; Jena, N. and Croce, C.M. Inactivation of Bcl-2 by phosphorylation. Proc. Natl. Acad. Sci. U.S.A., 1995, 92, 4507-4511.
77. Poommipanit, P.B.; Chen, B. and Oltvai, Z.N. Interleukin-3 induces the phosphorylation of a distinct fraction of bcl-2. J. Biol. Chem., 1999, 274, 1033-1039.
78. Niles, R.M.; McFarland, M.; Weimer, M.B.; Redkar, A.; Fu, Y.M. and Meadows, G.G. Resveratrol is a potent inducer of apoptosis in human melanoma cells. Cancer Lett., 2003, 190, 157-163. (Pubitemid 36136014)
79. She, Q.B.; Huang, C.; Zhang, Y. and Dong, Z. Involvement of c-jun NH(2)- terminal kinases in resveratrol-induced activation of p53 and apoptosis. Mol. Carcinog., 2002, 33, 244-250. (Pubitemid 34297132)
80. She, Q.B.; Bode, A.M.; Ma, W.Y.; Chen, N.Y. and Dong, Z. Resveratrolinduced activation of p53 and apoptosis is mediated by extracellular-signalregulated protein kinases and p38 kinase. Cancer Res., 2001, 61, 1604-1610. (Pubitemid 34292594)
81. Shih, A.; Davis, F.B.; Lin, H.Y. and Davis, P.J. Resveratrol induces apoptosis in thyroid cancer cell lines via a MAPK- and p53-dependent mechanism. J. Clin. Endocrinol. Metab., 2002, 87, 1223-1232. (Pubitemid 36121092)
82. Nguyen, T.H.; Mustafa, F.B.; Pervaiz, S.; Ng, F.S. and Lim, L.H. ERK1/2 activation is required for resveratrol-induced apoptosis in MDA-MB-231 cells. Int. J. Oncol., 2008, 33, 81-92.
83. Pozo-Guisado, E.; Lorenzo-Benayas, M.J. and Fernandez-Salguero, P.M. Resveratrol modulates the phosphoinositide 3-kinase pathway through an estrogen receptor alpha-dependent mechanism: Relevance in cell proliferation. Int. J. Cancer, 2004, 109, 167-173. (Pubitemid 38240916)
84. Waite, K.A.; Sinden, M.R. and Eng, C. Phytoestrogen exposure elevates PTEN levels. Hum. Mol. Genet., 2005, 14, 1457-1463. (Pubitemid 40823455)
85. Li, T.; Wang, W.; Chen, H.; Li, T.; Ye, L. Evaluation of anti-leukemia effect of resveratrol by modulating SATA3 signaling. Int. Immunopharmacol., 2010, 10, 18-25.
86. Madan, E.; Prasad, S.; Roy, P.; George, J. and Shukla, Y. Regulation of apoptosis by resveratrol through JAK/STAT and mitochondria mediated pathway in human epidermoid carcinoma A431 cells. Biochem. Biophys. Res. Commun., 2008, 377, 1232-1237.
87. Yu, L.J.; Wu, M.L.; Li, H.; Chen, X.Y.; Wang, Q.; Sun, Y.; Kong, Q.Y. and Liu, J. Inhibition of STAT3 expression and signaling in resveratroldifferentiated medulloblastoma cells. Neoplasia, 2008, 10, 736-744. (Pubitemid 351883890)
88. Ivanov, V.N.; Partridge, M.A.; Johnson, G.E.; Huang, S.X.; Zhou, H. and Hei, T.K. Resveratrol sensitizes melanomas to TRAIL through modulation of antiapoptotic gene expression. Exp. Cell Res., 2008, 314, 1163-1176.
89. Johnson, G.E.; Ivanov, V.N. and Hei, T.K. Radiosensitization of melanoma cells through combined inhibition of protein regulators of cell survival. Apoptosis, 2008, 13, 790-802.
90. Sallman, D.A.; Chen, X.; Zhong, B.; Gilvary, D.L.; Zhou, J.; Wei, S. and Djeu, J.Y. Clusterin mediates TRAIL resistance in prostate tumor cells. Mol. Cancer Ther., 2007, 6, 2938-2947. (Pubitemid 350206772)
91. Mohan, J.; Gandhi, A.A.; Bhavya, B.C.; Rashmi, R.; Karunagaran, D.; Indu, R. and Santhoshkumar, T.R. Caspase-2 triggers Bax-Bak dependent and independent cell death in colon cancer cells treated with resveratrol. J. Biol. Chem., 2006, 281, 17599-17611. (Pubitemid 44035559)
92. Kim, Y.A.; Rhee, S.H.; Park, K.Y. and Choi, Y.H. Antiproliferative effect of resveratrol in human prostate carcinoma cells. J. Med. Food, 2003, 6, 273-280. (Pubitemid 38114319)
93. Liontas, A. and Yeger, H. Curcumin and resveratrol induce apoptosis and nuclear translocation and activation of p53 in human neuroblastoma. Anticancer Res., 2004, 24, 987-998. (Pubitemid 38625049)
94. Kim, S.; Min, S.Y.; Lee, S.K. and Cho, W.J. Comparative molecular field analysis study of stilbene derivatives active against A549 lung carcinoma. Chem. Pharm. Bull. (Tokyo), 2003, 51, 516-521. (Pubitemid 41656802)
95. Jiang, H.; Zhang, L.; Kuo, J.; Kuo, K.; Gautam, S.C.; Groc, L.; Rodriguez, A.I.; Koubi, D.; Hunter, T.J.; Corcoran, G.B.; Seidman, M.D. and Levine, R.A. Resveratrol-induced apoptotic death in human U251 glioma cells. Mol. Cancer Ther., 2005, 4, 554-561. (Pubitemid 40601836)
96. Luzi, C.; Brisdelli, F.; Cinque, B.; Cifone, G. and Bozzi, A. Differential sensitivity to resveratrol-induced apoptosis of human chronic myeloid (K562) and acute lymphoblastic (HSB-2) leukemia cells. Biochem. Pharmacol., 2004, 68, 2019-2030. (Pubitemid 39346192)
97. Mahyar-Roemer, M.; Kohler, H. and Roemer, K. Role of Bax in resveratrolinduced apoptosis of colorectal carcinoma cells. BMC Cancer, 2002, 2, 27.
98. Kuo, P.L.; Chiang, L.C. and Lin, C.C. Resveratrol- induced apoptosis is mediated by p53-dependent pathway in Hep G2 cells. Life Sci., 2002, 72, 23-34.
99. Mahyar-Roemer, M.; Katsen, A.; Mestres, P. and Roemer, K. Resveratrol induces colon tumor cell apoptosis independently of p53 and precede by epithelial differentiation, mitochondrial proliferation and membrane potential collapse. Int. J. Cancer, 2001, 94, 615-622. (Pubitemid 33035679)
100. Wei, M.C.; Zong, W.X.; Cheng, E.H.; Lindsten, T.; Panoutsakopoulou, V.; Ross, A.J.; Roth, K.A.; MacGregor, G.R.; Thompson, C.B. and Korsmeyer, S.J. Proapoptotic BAX and BAK: A requisite gateway to mitochondrial dysfunction and death. Science, 2001, 292, 727-730. (Pubitemid 32385543)
101. Pohland, T.; Wagner, S.; Mahyar-Roemer, M. and Roemer, K. Bax and Bak are the critical complementary effectors of colorectal cancer cell apoptosis by chemopreventive resveratrol. Anticancer Drugs, 2006, 17, 471-478. (Pubitemid 44309991)
102. Tinel, A. and Tschopp, J. The PIDDosome, a protein complex implicated in activation of caspase-2 in response to genotoxic stress. Science, 2004, 304, 843-846. (Pubitemid 38620177)
103. Tessitore, L.; Davit, A.; Sarotto, I. and Caderni, G. Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21(CIP) expression. Carcinogenesis, 2000, 21, 1619-1622. (Pubitemid 30608219)
104. Aziz, M.H.; Afaq, F. and Ahmad, N. Prevention of ultraviolet-B radiation damage by resveratrol in mouse skin is mediated via modulation in survivin. Photochem. Photobiol., 2005, 81, 25-31. (Pubitemid 40327556)
105. Du, C.; Fang, M.; Li, Y.; Li, L. and Wang, X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell, 2000, 102, 33-42.
106. Srinivasula, S.M.; Datta, P.; Fan, X.J.; Fernandes-Alnemri, T.; Huang, Z. and Alnemri, E.S. Molecular determinants of the caspase-promoting activity of Smac/DIABLO and its role in the death receptor pathway. J. Biol. Chem., 2000, 275, 36152-36157.
107. Hayashibara, T.; Yamada, Y.; Nakayama, S.; Harasawa, H.; Tsuruda, K.; Sugahara, K.; Miyanishi, T.; Kamihira, S.; Tomonaga, M. and Maita, T. Resveratrol induces downregulation in survivin expression and apoptosis in HTLV-1-infected cell lines: A prospective agent for adult T cell leukemia chemotherapy. Nutr. Cancer, 2002, 44, 193-201.
108. Fulda, S. and Debatin, K.M. Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res., 2004, 64, 337-346. (Pubitemid 38114116)
109. Harbour, J.W. and Dean, D.C. The Rb/E2F pathway: Expanding roles and emerging paradigms. Genes. Dev., 2000, 14, 2393-2409.
110. Colin, D.; Gimazane, A.; Lizard, G.; Izard, J.C.; Solary, E.; Latruffe, N. and Delmas, D. Effects of resveratrol analogs on cell cycle progression, cell cycle associated proteins and 5fluoro-uracil sensitivity in human derived colon cancer cells. Int. J. Cancer, 2009, 124, 2780-2788.
111. Greenblatt, M.S.; Bennett, W.P.; Hollstein, M. and Harris, C.C. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res., 1994, 54, 4855-4878. (Pubitemid 24289415)
112. Kastan, M.B.; Zhan, Q.; el-Deiry, W.S.; Carrier, F.; Jacks, T.; Walsh, W.V.; Plunkett, B.S.; Vogelstein, B. and Fornace, A.J., Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxiatelangiectasia. Cell, 1992, 71, 587-597.
113. Barak, Y.; Juven, T.; Haffner, R. and Oren, M. mdm2 expression is induced by wild type p53 activity. EMBO J., 1993, 12, 461-468. (Pubitemid 23073692)
114. Hsieh, T.C.; Juan, G.; Darzynkiewicz, Z. and Wu, J.M. Resveratrol increases nitric oxide synthase, induces accumulation of p53 and p21(WAF1/CIP1), and suppresses cultured bovine pulmonary artery endothelial cell proliferation by perturbing progression through S and G2. Cancer Res., 1999, 59, 2596-2601. (Pubitemid 29269105)
115. Huang, C.; Ma, W.Y.; Goranson, A. and Dong, Z. Resveratrol suppresses cell transformation and induces apoptosis through a p53-dependent pathway. Carcinogenesis, 1999, 20, 237-242. (Pubitemid 29057555)
116. Tsan, M.F.; White, J.E.; Maheshwari, J.G.; Bremner, T.A. and Sacco, J. Resveratrol induces Fas signalling-independent apoptosis in THP-1 human monocytic leukaemia cells. Br. J. Haematol., 2000, 109, 405-412. (Pubitemid 30350725)
117. Mahyar-Roemer, M. and Roemer, K. p21 Waf1/Cip1 can protect human colon carcinoma cells against p53-dependent and p53-independent apoptosis induced by natural chemopreventive and therapeutic agents. Oncogene, 2001, 20, 3387-3398. (Pubitemid 32588987)
118. Bernhard, D.; Tinhofer, I.; Tonko, M.; Hubl, H.; Ausserlechner, M.J.; Greil, R.; Kofler, R. and Csordas, A. Resveratrol causes arrest in the S-phase prior to Fas-independent apoptosis in CEM-C7H2 acute leukemia cells. Cell Death Differ., 2000, 7, 834-842.
119. Laux, M.T.; Aregullin, M.; Berry, J.P.; Flanders, J.A. and Rodriguez, E. Identification of a p53-dependent pathway in the induction of apoptosis of human breast cancer cells by the natural product, resveratrol. J. Altern. Complement. Med, 2004, 10, 235-239. (Pubitemid 38525728)
120. Dong, Z. Effects of food factors on signal transduction pathways. Biofactors, 2000, 12, 17-28. (Pubitemid 32107380)
121. Lin, H.Y.; Shih, A.; Davis, F.B.; Tang, H.Y.; Martino, L.J.; Bennett, J.A. and Davis, P.J. Resveratrol induced serine phosphorylation of p53 causes apoptosis in a mutant p53 prostate cancer cell line. J. Urol., 2002, 168, 748-755. (Pubitemid 34793357)
122. Young, L.F.; Hantz, H.L. and Martin, K.R. Resveratrol modulates gene expression associated with apoptosis, proliferation and cell cycle in cells with mutated human c-Ha-Ras, but does not alter c-Ha-Ras mRNA or protein expression. J. Nutr. Biochem., 2005, 16, 663-674. (Pubitemid 41456709)
123. Tyagi, A.; Singh, R.P.; Agarwal, C.; Siriwardana, S.; Sclafani, R.A. and Agarwal, R. Resveratrol causes Cdc2-tyr15 phosphorylation via ATM/ATRChk1/ 2-Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells. Carcinogenesis, 2005, 26, 1978-1987. (Pubitemid 41631273)
124. Shimizu, T.; Nakazato, T.; Xian, M.J.; Sagawa, M.; Ikeda, Y. and Kizaki, M. Resveratrol induces apoptosis of human malignant B cells by activation of caspase-3 and p38 MAP kinase pathways. Biochem. Pharmacol., 2006, 71, 742-750. (Pubitemid 43208830)
125. Anwar, A.; Siegel, D.; Kepa, J.K. and Ross, D. Interaction of the molecular chaperone Hsp70 with human NAD(P)H:quinone oxidoreductase 1. J. Biol. Chem., 2002, 277, 14060-14067. (Pubitemid 34968016)
126. Asher, G.; Lotem, J.; Kama, R.; Sachs, L. and Shaul, Y. NQO1 stabilizes p53 through a distinct pathway. Proc. Natl. Acad. Sci. U.S.A., 2002, 99, 3099-3104. (Pubitemid 34240592)
127. Asher, G.; Lotem, J.; Sachs, L.; Kahana, C. and Shaul, Y. Mdm-2 and ubiquitin- independent p53 proteasomal degradation regulated by NQO1. Proc. Natl. Acad. Sci. U.S.A., 2002, 99, 13125-13130.
128. Chance, B.; Ernster, L.; Garland, P.B.; Lee, C.P.; Light, P.A.; Ohnishi, T.; Ragan, C.I. and Wong, D. Flavoproteins of the mitochondrial respiratory chain. Proc. Natl. Acad. Sci. U.S.A., 1967, 57, 1498-1505.
129. Siegel, D.; Bolton, E.M.; Burr, J.A.; Liebler, D.C. and Ross, D. The reduction of alpha-tocopherolquinone by human NAD(P)H: Quinone oxidoreductase: The role of alpha-tocopherolhydroquinone as a cellular antioxidant. Mol. Pharmacol., 1997, 52, 300-305. (Pubitemid 27349622)
130. Yang, S.H.; Kim, J.S.; Oh, T.J.; Kim, M.S.; Lee, S.W.; Woo, S.K.; Cho, H.S.; Choi, Y.H.; Kim, Y.H.; Rha, S.Y.; Chung, H.C. and An, S.W. Genome- scale analysis of resveratrol-induced gene expression profile in human ovarian cancer cells using a cDNA microarray. Int. J. Oncol., 2003, 22, 741-750.
131. Bech-Otschir, D.; Seeger, M. and Dubiel, W. The COP9 signalosome: At the interface between signal transduction and ubiquitin-dependent proteolysis. J. Cell Sci., 2002, 115, 467-473. (Pubitemid 34182974)
132. Uhle, S.; Medalia, O.; Waldron, R.; Dumdey, R.; Henklein, P.; Bech-Otschir, D.; Huang, X.; Berse, M.; Sperling, J.; Schade, R. and Dubiel, W. Protein kinase CK2 and protein kinase D are associated with the COP9 signalosome. EMBO J., 2003, 22, 1302-1312. (Pubitemid 36362694)
133. Yoon, S.H.; Kim, Y.S.; Ghim, S.Y.; Song, B.H. and Bae, Y.S. Inhibition of protein kinase CKII activity by resveratrol, a natural compound in red wine and grapes. Life Sci., 2002, 71, 2145-2152.
134. Kawai, H.; Nie, L.; Wiederschain, D. and Yuan, Z.M. Dual role of p300 in the regulation of p53 stability. J. Biol. Chem., 2001, 276, 45928-45932.
135. Gu, W. and Roeder, R.G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell, 1997, 90, 595-606. (Pubitemid 27357952)
136. Narayanan, B.A.; Narayanan, N.K.; Re, G.G. and Nixon, D.W. Differential expression of genes induced by resveratrol in LNCaP cells: P53-mediated molecular targets. Int. J. Cancer, 2003, 104, 204-212. (Pubitemid 36249796)
137. Narayanan, B.A.; Narayanan, N.K.; Stoner, G.D. and Bullock, B.P. Interactive gene expression pattern in prostate cancer cells exposed to phenolic antioxidants. Life Sci., 2002, 70, 1821-1839. (Pubitemid 34178367)
138. Lee, D.Y.; Hayes, J.J.; Pruss, D. and Wolffe, A.P. A positive role for histone acetylation in transcription factor access to nucleosomal DNA. Cell, 1993, 72, 73-84. (Pubitemid 23029694)
139. Imhof, A.; Yang, X.J.; Ogryzko, V.V.; Nakatani, Y.; Wolffe, A.P. and Ge, H. Acetylation of general transcription factors by histone acetyltransferases. Curr. Biol., 1997, 7, 689-692. (Pubitemid 27408867)
140. Lill, N.L.; Grossman, S.R.; Ginsberg, D.; DeCaprio, J. and Livingston,
141. Zhang, S.; Cao, H.J.; Davis, F.B.; Tang, H.Y.; Davis, P.J. and Lin, H.Y. Oestrogen inhibits resveratrol-induced post-translational modification of p53 and apoptosis in breast cancer cells. Br. J. Cancer, 2004.
142. Kai, L.; Samuel, S.K. and Levenson, A.S. Resveratrol enhances p53 acetylation and apoptosis in prostate cancer by inhibiting MTA1/NuRD complex. Int. J. Cancer, 2010, 126, 1538-1548.
143. Frankel, D. and Schipper, H.M. Cysteamine pretreatment of the astroglial substratum (mitochondrial iron sequestration) enhances PC12 cell vulnerability to oxidative injury. Exp. Neurol., 1999, 160, 376-385.
144. Frankel, E.N.; Waterhouse, A.L. and Kinsella, J.E. Inhibition of human LDL oxidation by resveratrol. Lancet, 1993, 341, 1103-1104. (Pubitemid 23114451)
145. Reichard, P. Regulation of deoxyribotide synthesis. Biochemistry, 1987, 26, 3245-3248.
146. May, P. and May, E. Twenty years of p53 research: Structural and functional aspects of the p53 protein. Oncogene, 1999, 18, 7621-7636. (Pubitemid 30052689)
147. Macleod, K.F.; Sherry, N.; Hannon, G.; Beach, D.; Tokino, T.; Kinzler, K.; Vogelstein, B. and Jacks, T. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes. Dev., 1995, 9, 935-944.
148. Sherr, C.J. G1 phase progression: Cycling on cue. Cell, 1994, 79, 551-555. (Pubitemid 24363798)
149. Agarwal, M.L.; Taylor, W.R.; Chernov, M.V.; Chernova, O.B. and Stark, G.R. The p53 network. J. Biol. Chem., 1998, 273, 1-4. (Pubitemid 28042164)
150. Mitchell, S.H.; Zhu, W. and Young, C.Y. Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res., 1999, 59, 5892-5895. (Pubitemid 30004946)
151. Pozo-Guisado, E.; Alvarez-Barrientos, A.; Mulero-Navarro, S.; Santiago- Josefat, B. and Fernandez-Salguero, P.M. The antiproliferative activity of resveratrol results in apoptosis in MCF-7 but not in MDA-MB-231 human breast cancer cells: Cell-specific alteration of the cell cycle. Biochem. Pharmacol., 2002, 64, 1375-1386. (Pubitemid 35248254)
152. Jeong, S.H.; Jo, W.S.; Song, S.; Suh, H.; Seol, S.Y.; Leem, S.H.; Kwon, T.K. and Yoo, Y.H. A novel resveratrol derivative, HS1793, overcomes the resistance conferred by Bcl-2 in human leukemic U937 cells. Biochem. Pharmacol., 2009, 77, 1337-1347.
153. Jeong, S.H.; Lee, J.S.; Jeong, N.Y.; Kim, T.H.; Yoo, K.S.; Song, S.; Suh, H.; Kwon, T.K.; Park, B.S. and Yoo, Y.H. A novel resveratrol analogue HS- 1793 treatment overcomes the resistance conferred by Bcl-2 and is associated with the formation of mature PML nuclear bodies in renal clear cell carcinoma Caki-1 cells. Int. J. Oncol., 2009, 35, 1353-1360.
154. Biasutto, L.; Mattarei, A.; Marotta, E.; Bradaschia, A.; Sassi, N.; Garbisa, S.; Zoratti, M. and Paradisi, C. Development of mitochondria-targeted derivatives of resveratrol. Bioorg. Med. Chem. Lett., 2008, 18, 5594-5597.
155. Savio, M.; Coppa, T.; Bianchi, L.; Vannini, V.; Maga, G.; Forti, L.; Cazzalini, O.; Lazze, M.C.; Perucca, P.; Prosperi, E. and Stivala, L.A. The resveratrol analogue 4,4'-dihydroxy-trans-stilbene inhibits cell proliferation with higher efficiency but different mechanism from resveratrol. Int. J. Biochem. Cell Biol., 2009, 41, 2493-2502.
156. Murias, M.; Luczak, M.W.; Niepsuj, A.; Krajka-Kuzniak, V.; Zielinska- Przyjemska, M.; Jagodzinski, P.P.; Jager, W.; Szekeres, T. and Jodynis- Liebert, J. Cytotoxic activity of 3,3',4,4',5,5'-hexahydroxystilbene against breast cancer cells is mediated by induction of p53 and downregulation of mitochondrial superoxide dismutase. Toxicol. In Vitro, 2008, 22, 1361-1370.
157. Weng, C.J.; Yang, Y.T.; Ho, C.T. and Yen, G.C. Mechanisms of apoptotic effects induced by resveratrol, dibenzoylmethane, and their analogues on human lung carcinoma cells. J. Agric. Food Chem., 2009, 57, 5235-5243.
158. Gosslau, A.; Chen, M.; Ho, C.T. and Chen, K.Y. A methoxy derivative of resveratrol analogue selectively induced activation of the mitochondrial apoptotic pathway in transformed fibroblasts. Br. J. Cancer, 2005, 92, 513-521. (Pubitemid 40395532)
159. Gosslau, A.; Pabbaraja, S.; Knapp, S. and Chen, K.Y. Trans- and cis-stilbene polyphenols induced rapid perinuclear mitochondrial clustering and p53- independent apoptosis in cancer cells but not normal cells. Eur. J. Pharmacol., 2008, 587, 25-34.
160. Dorrie, J.; Gerauer, H.; Wachter, Y. and Zunino, S.J. Resveratrol induces extensive apoptosis by depolarizing mitochondrial membranes and activating caspase-9 in acute lymphoblastic leukemia cells. Cancer Res., 2001, 61, 4731-4739. (Pubitemid 32691883)
161. Ashkenazi, A. and Dixit, V.M. Death receptors: Signaling and modulation. Science, 1998, 281, 1305-1308. (Pubitemid 28406815)
162. Krammer, P.H. CD95(APO-1/Fas)-mediated apoptosis: Live and let die. Adv. Immunol., 1999, 71, 163-210. (Pubitemid 30227734)
163. Smith, C.A.; Farrah, T. and Goodwin, R.G. The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death. Cell, 1994, 76, 959-962. (Pubitemid 24106376)
164. Pinkoski, M.J. and Green, D.R. Fas ligand, death gene. Cell Death Differ., 1999, 6, 1174-1181. (Pubitemid 30047894)
165. Muzio, M.; Chinnaiyan, A.M.; Kischkel, F.C.; O'Rourke, K.; Shevchenko, A.; Ni, J.; Scaffidi, C.; Bretz, J.D.; Zhang, M.; Gentz, R.; Mann, M.; Krammer, P.H.; Peter, M.E. and Dixit, V.M. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death- inducing signaling complex. Cell, 1996, 85, 817-827. (Pubitemid 26193033)
166. Jiang, S.; Song, M.J.; Shin, E.C.; Lee, M.O.; Kim, S.J. and Park, J.H. Apoptosis in human hepatoma cell lines by chemotherapeutic drugs via Fasdependent and Fas-independent pathways. Hepatology, 1999, 29, 101-110. (Pubitemid 29023992)
167. Wang, Q.; Li, H.; Wang, X.W.; Wu, D.C.; Chen, X.Y. and Liu, J. Resveratrol promotes differentiation and induces Fas-independent apoptosis of human medulloblastoma cells. Neurosci. Lett., 2003, 351, 83-86. (Pubitemid 37329594)
168. Micheau, O.; Solary, E.; Hammann, A. and Dimanche-Boitrel, M.T. Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. J. Biol. Chem., 1999, 274, 7987-7992.
169. Hueber, A.O.; Bernard, A.M.; Herincs, Z.; Couzinet, A. and He, H.T. An essential role for membrane rafts in the initiation of Fas/CD95-triggered cell death in mouse thymocytes. EMBO Rep., 2002, 3, 190-196. (Pubitemid 34213499)
170. Grassme, H.; Jekle, A.; Riehle, A.; Schwarz, H.; Berger, J.; Sandhoff, K.; Kolesnick, R. and Gulbins, E. CD95 signaling via ceramide-rich membrane rafts. J. Biol. Chem., 2001, 276, 20589-20596.
171. Delmas, D.; Rebe, C.; Micheau, O.; Athias, A.; Gambert, P.; Grazide, S.; Laurent, G.; Latruffe, N. and Solary, E. Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. Oncogene, 2004, 23, 8979-8986. (Pubitemid 39657788)
172. Gajate, C. and Mollinedo, F. The antitumor ether lipid ET-18-OCH(3) induces apoptosis through translocation and capping of Fas/CD95 into membrane rafts in human leukemic cells. Blood, 2001, 98, 3860-3863.
173. Su, J.L.; Lin, M.T.; Hong, C.C.; Chang, C.C.; Shiah, S.G.; Wu, C.W.; Chen, S.T.; Chau, Y.P. and Kuo, M.L. Resveratrol induces FasL-related apoptosis through Cdc42 activation of ASK1/JNK-dependent signaling pathway in human leukemia HL-60 cells. Carcinogenesis, 2005, 26, 1-10.
174. Barry, M.A.; Behnke, C.A. and Eastman, A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem. Pharmacol., 1990, 40, 2353-2362. (Pubitemid 20373997)
175. Santana, P.; Pena, L.A.; Haimovitz-Friedman, A.; Martin, S.; Green, D.; McLoughlin, M.; Cordon-Cardo, C.; Schuchman, E.H.; Fuks, Z. and Kolesnick, R. Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell, 1996, 86, 189-199. (Pubitemid 26286102)
176. Hannun, Y.A.; Luberto, C. and Argraves, K.M. Enzymes of sphingolipid metabolism: From modular to integrative signaling. Biochemistry, 2001, 40, 4893-4903. (Pubitemid 32332534)
177. Spiegel, S.; Foster, D. and Kolesnick, R. Signal transduction through lipid second messengers. Curr. Opin. Cell Biol., 1996, 8, 159-167. (Pubitemid 26109088)
178. Scarlatti, F.; Sala, G.; Somenzi, G.; Signorelli, P.; Sacchi, N. and Ghidoni, R. Resveratrol induces growth inhibition and apoptosis in metastatic breast cancer cells via de novo ceramide signaling. FASEB J., 2003, 17, 2339-2341. (Pubitemid 39561486)
179. Sala, G.; Minutolo, F.; Macchia, M.; Sacchi, N. and Ghidoni, R. Resveratrol structure and ceramide-associated growth inhibition in prostate cancer cells. Drugs Exp. Clin. Res., 2003, 29, 263-269. (Pubitemid 38568633)
180. Minutolo, F.; Sala, G.; Bagnacani, A.; Bertini, S.; Carboni, I.; Placanica, G.; Prota, G.; Rapposelli, S.; Sacchi, N.; Macchia, M. and Ghidoni, R. Synthesis of a resveratrol analogue with high ceramide-mediated proapoptotic activity on human breast cancer cells. J. Med. Chem., 2005, 48, 6783-6786. (Pubitemid 41533099)
181. Slater, S.J.; Seiz, J.L.; Cook, A.C.; Stagliano, B.A. and Buzas, C.J. Inhibition of protein kinase C by resveratrol. Biochim. Biophys. Acta, 2003, 1637, 59-69. (Pubitemid 36071597)
182. Tou, J. and Urbizo, C. Resveratrol inhibits the formation of phosphatidic acid and diglyceride in chemotactic peptide- or phorbol ester-stimulated human neutrophils. Cell Signal., 2001, 13, 191-197. (Pubitemid 32244403)
183. Stewart, J.R.; Ward, N.E.; Ioannides, C.G. and O'Brian, C.A. Resveratrol preferentially inhibits protein kinase C-catalyzed phosphorylation of a cofactor- independent, arginine-rich protein substrate by a novel mechanism. Biochemistry, 1999, 38, 13244-13251.
184. Atten, M.J.; Attar, B.M.; Milson, T. and Holian, O. Resveratrol-induced inactivation of human gastric adenocarcinoma cells through a protein kinase C-mediated mechanism. Biochem. Pharmacol., 2001, 62, 1423-1432. (Pubitemid 33044689)
185. Jayatilake, G.S.; Jayasuriya, H.; Lee, E.S.; Koonchanok, N.M.; Geahlen, R.L.; Ashendel, C.L.; McLaughlin, J.L. and Chang, C.J. Kinase inhibitors from Polygonum cuspidatum. J. Nat. Prod., 1993, 56, 1805-1810. (Pubitemid 23326302)
186. Subbaramaiah, K.; Chung, W.J.; Michaluart, P.; Telang, N.; Tanabe, T.; Inoue, H.; Jang, M.; Pezzuto, J.M. and Dannenberg, A.J. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J. Biol. Chem. 1998, 273, 21875-21882. (Pubitemid 28405365)
187. Stewart, J.R.; Christman, K.L. and O'Brian, C.A. Effects of resveratrol on the autophosphorylation of phorbol ester-responsive protein kinases: Inhibition of protein kinase D but not protein kinase C isozyme autophosphorylation. Biochem. Pharmacol., 2000, 60, 1355-1359.
188. Haworth, R.S. and Avkiran, M. Inhibition of protein kinase D by resveratrol. Biochem. Pharmacol., 2001, 62, 1647-1651. (Pubitemid 34033651)
189. Storz, P.; Doeppler, H.; Toker, A. Activation Loop Phosphorylation Controls Protein Kinase D-Dependent Activation of Nuclear Factor {kappa}-B. Mol. Pharmacol., 2004, 66, 870-879. (Pubitemid 39319459)
190. Beg, A.A.; Sha, W.C.; Bronson, R.T.; Ghosh, S. and Baltimore, D. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature, 1995, 376, 167-170.
191. Karin, M. and Lin, A. NF-kappaB at the crossroads of life and death. Nat. Immunol., 2002, 3, 221-227.
192. Wang, C.Y.; Cusack, J.C., Jr.; Liu, R. and Baldwin, A.S., Jr. Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat. Med., 1999, 5, 412-417. (Pubitemid 29180579)
193. Draczynska-Lusiak, B.; Chen, Y.M. and Sun, A.Y. Oxidized lipoproteins activate NF-kappaB binding activity and apoptosis in PC12 cells. Neuroreport, 1998, 9, 527-532. (Pubitemid 28109217)
194. Holmes-McNary, M. and Baldwin, A.S., Jr. Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IkappaB kinase. Cancer. Res., 2000, 60, 3477-3483. (Pubitemid 30482167)
195. Adhami, V.M.; Afaq, F. and Ahmad, N. Suppression of ultraviolet B exposure- mediated activation of NF-kappaB in normal human keratinocytes by resveratrol. Neoplasia, 2003, 5, 74-82. (Pubitemid 36151060)
196. Manna, S.K.; Mukhopadhyay, A. and Aggarwal, B.B. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: Potential role of reactive oxygen intermediates and lipid peroxidation. J. Immunol., 2000, 164, 6509-6519. (Pubitemid 30408836)
197. Pendurthi, U.R.; Meng, F.; Mackman, N. and Rao, L.V. Mechanism of resveratrol-mediated suppression of tissue factor gene expression. Thromb. Haemost., 2002, 87, 155-162. (Pubitemid 34092591)
198. Jo, E.H.; Hong, H.D.; Ahn, N.C.; Jung, J.W.; Yang, S.R.; Park, J.S.; Kim, S.H.; Lee, Y.S. and Kang, K.S. Modulations of the Bcl-2/Bax family were involved in the chemopreventive effects of licorice root (Glycyrrhiza uralensis Fisch) in MCF-7 human breast cancer cell. J. Agric. Food Chem., 2004, 52, 1715-1719.
199. Taylor, B.S.; de Vera, M.E.; Ganster, R.W.; Wang, Q.; Shapiro, R.A.; Morris, S.M., Jr.; Billiar, T.R. and Geller, D.A. Multiple NF-kappaB enhancer elements regulate cytokine induction of the human inducible nitric oxide synthase gene. J. Biol. Chem., 1998, 273, 15148-15156. (Pubitemid 28272813)
200. Sheppard, K.A.; Phelps, K.M.; Williams, A.J.; Thanos, D.; Glass, C.K.; Rosenfeld, M.G.; Gerritsen, M.E. and Collins, T. Nuclear integration of glucocorticoid receptor and nuclear factor-kappaB signaling by CREB-binding protein and steroid receptor coactivator-1. J. Biol. Chem., 1998, 273, 29291-29294. (Pubitemid 28509926)
201. Sheppard, K.A.; Rose, D.W.; Haque, Z.K.; Kurokawa, R.; McInerney, E.; Westin, S.; Thanos, D.; Rosenfeld, M.G.; Glass, C.K. and Collins, T. Transcriptional activation by NF-kappaB requires multiple coactivators. Mol. Cell Biol., 1999, 19, 6367-6378. (Pubitemid 29399341)
202. Zhong, H.; May, M.J.; Jimi, E. and Ghosh, S. The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1. Mol. Cell, 2002, 9, 625-636. (Pubitemid 34273792)
203. Howitz, K.T.; Bitterman, K.J.; Cohen, H.Y.; Lamming, D.W.; Lavu, S.; Wood, J.G.; Zipkin, R.E.; Chung, P.; Kisielewski, A.; Zhang, L.L.; Scherer, B. and Sinclair, D.A. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature, 2003, 425, 191-196. (Pubitemid 37150899)
204. Yeung, F.; Hoberg, J.E.; Ramsey, C.S.; Keller, M.D.; Jones, D.R.; Frye, R.A.; Mayo, M.W. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J., 2004, 23, 2369-2380. (Pubitemid 38954844)
205. Donnelly, L.E.; Newton, R.; Kennedy, G.E.; Fenwick, P.S.; Leung, R.H.; Ito, K.; Russell, R.E. and Barnes, P.J. Anti-inflammatory effects of resveratrol in lung epithelial cells: Molecular mechanisms. Am. J. Physiol. Lung Cell Mol. Physiol., 2004, 287, L774-783. (Pubitemid 39249390)
206. Subbaramaiah, K.; Michaluart, P.; Chung, W.J.; Tanabe, T.; Telang, N. and Dannenberg, A.J. Resveratrol inhibits cyclooxygenase-2 transcription in human mammary epithelial cells. Ann. N Y Acad. Sci., 1999, 889, 214-223. (Pubitemid 30040439)
207. Yu, R.; Hebbar, V.; Kim, D.W.; Mandlekar, S.; Pezzuto, J.M. and Kong, A.N. Resveratrol inhibits phorbol ester and UV-induced activator protein 1 activation by interfering with mitogen-activated protein kinase pathways. Mol. Pharmacol., 2001, 60, 217-224. (Pubitemid 32595249)
208. Karin, M. and Delhase, M. JNK or IKK, AP-1 or NF-kappaB, which are the targets for MEK kinase 1 action? Proc. Natl. Acad. Sci. U.S.A., 1998, 95, 9067-9069. (Pubitemid 28506184)
209. Lee, F.S.; Hagler, J.; Chen, Z.J. and Maniatis, T. Activation of the IkappaB alpha kinase complex by MEKK1, a kinase of the JNK pathway. Cell, 1997, 88, 213-222. (Pubitemid 28015870)
210. Shen, F.; Chen, S.J.; Dong, X.J.; Zhong, H.; Li, Y.T. and Cheng, G.F. Suppression of IL-8 gene transcription by resveratrol in phorbol ester treated human monocytic cells. J. Asian Nat. Prod. Res., 2003, 5, 151-157. (Pubitemid 36566099)
211. Yang, S. and Meyskens, F. Resveratrol induces AP-1 inhibition, altered AP-1 composition and increased expression of specific jun and fos family proteins in human Melanoma cells. Pigment. Cell Res., 2004, 17, 445.
212. Kroemer, G. and Jaattela, M. Lysosomes and autophagy in cell death control. Nat. Rev. Cancer, 2005, 5, 886-897. (Pubitemid 41746033)
213. Opipari, A.W., Jr.; Tan, L.; Boitano, A.E.; Sorenson, D.R.; Aurora, A. and Liu, J.R. Resveratrol-induced autophagocytosis in ovarian cancer cells. Cancer Res., 2004, 64, 696-703. (Pubitemid 38120912)
214. Kueck, A.; Opipari, A.W., Jr.; Griffith, K.A.; Tan, L.; Choi, M.; Huang, J.; Wahl, H. and Liu, J.R. Resveratrol inhibits glucose metabolism in human ovarian cancer cells. Gynecol. Oncol., 2007, 107, 450-457. (Pubitemid 350160855)
215. Trincheri, N.F.; Follo, C.; Nicotra, G.; Peracchio, C.; Castino, R. and Isidoro, C. Resveratrol-induced Apoptosis Depends on the Lipid Kinase Activity of Vps34 and on the Formation of Autophagolysosomes. Carcinogenesis, 2007, 29, 381-389. (Pubitemid 351359678)
216. Signorelli, P.; Munoz-Olaya, J.M.; Gagliostro, V.; Casas, J.; Ghidoni, R. and Fabrias, G. Dihydroceramide intracellular increase in response to resveratrol treatment mediates autophagy in gastric cancer cells. Cancer Lett., 2009, 282, 238-243.
217. Ohshiro, K.; Rayala, S.K.; El-Naggar, A.K. and Kumar, R. Delivery of cytoplasmic proteins to autophagosomes. Autophagy, 2008, 4, 104-106.
218. Ohshiro, K.; Rayala, S.K.; Kondo, S.; Gaur, A.; Vadlamudi, R.K.; El- Naggar, A.K. and Kumar, R. Identifying the estrogen receptor coactivator PELP1 in autophagosomes. Cancer Res., 2007, 67, 8164-8171. (Pubitemid 47395152)
219. Bertelli, A.A.; Ferrara, F.; Diana, G.; Fulgenzi, A.; Corsi, M.; Ponti, W.; Ferrero, M.E. and Bertelli, A. Resveratrol, a natural stilbene in grapes and wine, enhances intraphagocytosis in human promonocytes: A co-factor in antiinflammatory and anticancer chemopreventive activity. Int. J. Tissue. React., 1999, 21, 93-104. (Pubitemid 30186540)
220. Puissant, A.; Robert, G.; Fenouille, N.; Luciano, F.; Cassuto, J.P.; Raynaud, S. and Auberger, P. Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation. Cancer Res., 2010, 70, 1042-1052.
221. Ogier-Denis, E. and Codogno, P. Autophagy: A barrier or an adaptive response to cancer. Biochim. Biophys. Acta, 2003, 1603, 113-128. (Pubitemid 36266686)
222. Heiss, E.H.; Schilder, Y.D. and Dirsch, V.M. Chronic treatment with resveratrol induces redox stress- and ataxia telangiectasia-mutated (ATM)- dependent senescence in p53-positive cancer cells. J. Biol. Chem., 2007, 282, 26759-26766. (Pubitemid 47501966)
223. Young, L.F. and Martin, K.R. Time-dependent resveratrol-mediated mRNA and protein expression associated with cell cycle in WR-21 cells containing mutated human c-Ha-Ras. Mol. Nutr. Food Res., 2006, 50, 70-77. (Pubitemid 43155097)
224. Gatz, S.A.; Keimling, M.; Baumann, C.; Dork, T.; Debatin, K.M.; Fulda, S.; Wiesmuller, L. Resveratrol modulates DNA double-strand break repair pathways in an ATM/ATR-p53- and -Nbs1-dependent manner. Carcinogenesis, 2008, 29, 519-527. (Pubitemid 351404867)
225. Ling, X.; He, X.; Apontes, P.; Cao, F.; Azrak, R.G. and Li, F. Enhancing effectiveness of the MDR-sensitive compound T138067 using advanced treatment with negative modulators of the drug-resistant protein survivin. Am. J. Transl. Res., 2009, 1, 393-405.
226. Singh, N.; Nigam, M.; Ranjan, V.; Sharma, R.; Balapure, A.K. and Rath, S.K. Caspase mediated enhanced apoptotic action of cyclophosphamide- and resveratrol-treated mcf-7 cells. J. Pharmacol. Sci., 2009, 109, 473-485.
227. Wesierska-Gadek, J.; Kramer, M.P.; Maurer, M. Resveratrol modulates roscovitine-mediated cell cycle arrest of human MCF-7 breast cancer cells. Food Chem. Toxicol., 2007, 46, 1327-1333.
228. Fulda, S. and Debatin, K.M. Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol. Oncogene, 2004, 23, 6702-6711. (Pubitemid 39280002)
229. Kim, M.Y.; Trudel, L.J. and Wogan, G.N. Apoptosis induced by capsaicin and resveratrol in colon carcinoma cells requires nitric oxide production and caspase activation. Anticancer Res., 2009, 29, 3733-3740.
230. Chan, J.Y.; Phoo, M.S.; Clement, M.V.; Pervaiz, S. and Lee, S.C. Resveratrol displays converse dose-related effects on 5-fluorouracil-evoked colon cancer cell apoptosis: The roles of caspase-6 and p53. Cancer Biol. Ther., 2008, 7, 1305-1312.
231. Hwang, J.T.; Kwak, D.W.; Lin, S.K.; Kim, H.M.; Kim, Y.M.; Park, O.J. Resveratrol induces apoptosis in chemoresistant cancer cells via modulation of AMPK signaling pathway. Ann. N Y Acad. Sci., 2007, 1095, 441-448.
232. Sun, Z.J.; Pan, C.E.; Liu, H.S. and Wang, G.J. Anti-hepatoma activity of resveratrol in vitro. World J. Gastroenterol., 2002, 8, 79-81.
233. Morotti, A.; Cilloni, D.; Pautasso, M.; Messa, F.; Arruga, F.; Defilippi, I.; Carturan, S.; Catalano, R.; Rosso, V.; Chiarenza, A.; Taulli, R.; Bracco, E.; Rege-Cambrin, G.; Gottardi, E. and Saglio, G. NF-kB inhibition as a strategy to enhance etoposide-induced apoptosis in K562 cell line. Am. J. Hematol., 2006, 81, 938-945. (Pubitemid 44864452)
234. Reis-Sobreiro, M.; Gajate, C. and Mollinedo, F. Involvement of mitochondria and recruitment of Fas/CD95 signaling in lipid rafts in resveratrolmediated antimyeloma and antileukemia actions. Oncogene, 2009, 28, 3221-3234.
235. Horvath, Z.; Saiko, P.; Illmer, C.; Madlener, S.; Hoechtl, T.; Bauer, W.; Erker, T.; Jaeger, W.; Fritzer-Szekeres, M. and Szekeres, T. Resveratrol, an ingredient of wine, acts synergistically with Ara-C and tiazofurin in HL-60 human promyelocytic leukemia cells. Nucleosides Nucleotides Nucleic Acids, 2006, 25, 1019-1024. (Pubitemid 44651840)
236. Horvath, Z.; Saiko, P.; Illmer, C.; Madlener, S.; Hoechtl, T.; Bauer, W.; Erker, T.; Jaeger, W.; Fritzer-Szekeres, M. and Szekeres, T. Synergistic action of resveratrol, an ingredient of wine, with Ara-C and tiazofurin in HL-60 human promyelocytic leukemia cells. Exp. Hematol., 2005, 33, 329-335. (Pubitemid 40261314)
237. Quan, F.; Pan, C.; Ma, Q.; Zhang, S. and Yan, L. Reversal effect of resveratrol on multidrug resistance in KBv200 cell line. Biomed. Pharmacother., 2008, 62, 622-629.
238. Harikumar, K.B.; Kunnumakkara, A.B.; Sethi, G.; Diagaradjane, P.; Anand, P.; Pandey, M.K.; Gelovani, J.; Krishnan, S.; Guha, S.; Aggarwal, B.B. Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer. Int. J. Cancer, 2009, 127, 257-268.
239. Scifo, C.; Cardile, V.; Russo, A.; Consoli, R.; Vancheri, C.; Capasso, F.; Vanella, A. and Renis, M. Resveratrol and propolis as necrosis or apoptosis inducers in human prostate carcinoma cells. Oncol. Res., 2004, 14, 415-426. (Pubitemid 39304309)
240. Scifo, C.; Milasi, A.; Guarnera, A.; Sinatra, F. and Renis, M. Resveratrol and propolis extract: An insight into the morphological and molecular changes induced in DU145 cells. Oncol. Res., 2006, 15, 409-421.
241. Kubota, T.; Uemura, Y.; Kobayashi, M. and Taguchi, H. Combined effects of resveratrol and paclitaxel on lung cancer cells. Anticancer Res., 2003, 23, 4039-4046. (Pubitemid 37474362)
242. Fuggetta, M.P.; D'Atri, S.; Lanzilli, G.; Tricarico, M.; Cannavo, E.; Zambruno, G.; Falchetti, R. and Ravagnan, G. In vitro antitumour activity of resveratrol in human melanoma cells sensitive or resistant to temozolomide. Melanoma. Res., 2004, 14, 189-196. (Pubitemid 38879580)
243. Petersen, B.O.; Lukas, J.; Sorensen, C.S.; Bartek, J. and Helin, K. Phosphorylation of mammalian CDC6 by cyclin A/CDK2 regulates its subcellular localization. EMBO J., 1999, 18, 396-410. (Pubitemid 29041948)
244. Morgan, D.O. Principles of CDK regulation. Nature, 1995, 374, 131-134.
245. Girard, F.; Strausfeld, U.; Fernandez, A. and Lamb, N.J. Cyclin A is required for the onset of DNA replication in mammalian fibroblasts. Cell, 1991, 67, 1169-1179. (Pubitemid 121001529)
246. Cardoso, M.C.; Leonhardt, H. and Nadal-Ginard, B. Reversal of terminal differentiation and control of DNA replication: Cyclin A and Cdk2 specifically localize at subnuclear sites of DNA replication. Cell, 1993, 74, 979-992. (Pubitemid 23289456)
247. Maridor, G.; Gallant, P.; Golsteyn, R. and Nigg, E.A. Nuclear localization of vertebrate cyclin A correlates with its ability to form complexes with cdk catalytic subunits. J. Cell Sci., 1993, 106 (Pt. 2), 535-544. (Pubitemid 23309072)
248. Brenot-Bosc, F.; Gupta, S.; Margolis, R.L. and Fotedar, R. Changes in the subcellular localization of replication initiation proteins and cell cycle proteins during G1- to S-phase transition in mammalian cells. Chromosoma, 1995, 103, 517-527.
249. Alexandrow, M.G. and Hamlin, J.L. Cdc6 chromatin affinity is unaffected by serine-54 phosphorylation, S-phase progression, and overexpression of cyclin A. Mol. Cell Biol., 2004, 24, 1614-1627. (Pubitemid 38167083)
250. Kawashima, R.; Haisa, M.; Kimura, M.; Takaoka, M.; Shirakawa, Y.; Takeda, H.; Uetsuka, H.; Gunduz, M.; Nagai, N.; Tanaka, N. and Naomoto, Y. Cyclin A correlates with the sensitivity of human cancer cells to cytotoxic effects of 5-FU. Int. J. Oncol., 2004, 24, 273-278.
251. Trincheri, N.F.; Nicotra, G.; Follo, C.; Castino, R. and Isidoro, C. Resveratrol induces cell death in colorectal cancer cells by a novel pathway involving lysosomal cathepsin D. Carcinogenesis, 2007, 28, 922-931. (Pubitemid 47072174)
252. Luciani, F.; Spada, M.; De Milito, A.; Molinari, A.; Rivoltini, L.; Montinaro, A.; Marra, M.; Lugini, L.; Logozzi, M.; Lozupone, F.; Federici, C.; Iessi, E.; Parmiani, G.; Arancia, G.; Belardelli, F. and Fais, S. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J. Natl. Cancer Inst., 2004, 96, 1702-1713. (Pubitemid 39585639)
253. Raghunand, N.; Mahoney, B.P. and Gillies, R.J. Tumor acidity, ion trapping and chemotherapeutics. II. pH-dependent partition coefficients predict importance of ion trapping on pharmacokinetics of weakly basic chemotherapeutic agents. Biochem. Pharmacol., 2003, 66, 1219-1229. (Pubitemid 37130297)
254. Altan, N.; Chen, Y.; Schindler, M. and Simon, S.M. Defective acidification in human breast tumor cells and implications for chemotherapy. J. Exp. Med., 1998, 187, 1583-1598. (Pubitemid 28235100)
255. Larsen, A.K.; Escargueil, A.E. and Skladanowski, A. Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol. Ther., 2000, 85, 217-229. (Pubitemid 30160791)
256. Goad, K.E. and Gralnick, H.R. Coagulation disorders in cancer. Hematol. Oncol. Clin. North Am., 1996, 10, 457-484. (Pubitemid 26097347)
257. Olas, B. and Wachowicz, B. Modulation of cisplatin toxicity in blood platelets by glutathione depletion. Anticancer Drugs, 1998, 9, 473-478. (Pubitemid 28271980)
258. Rezk, Y.A.; Balulad, S.S.; Keller, R.S. and Bennett, J.A. Use of resveratrol to improve the effectiveness of cisplatin and doxorubicin: Study in human gynecologic cancer cell lines and in rodent heart. Am. J. Obstet. Gynecol., 2006, 194, e23-26.
259. Wang, J.; He, D.; Zhang, Q.; Han, Y.; Jin, S. and Qi, F. Resveratrol protects against Cisplatin-induced cardiotoxicity by alleviating oxidative damage. Cancer Biother. Radiopharm., 2009, 24, 675-680.
260. Olas, B.; Wachowicz, B.; Majsterek, I. and Blasiak, J. Resveratrol may reduce oxidative stress induced by platinum compounds in human plasma, blood platelets and lymphocytes. Anticancer Drugs, 2005, 16, 659-665. (Pubitemid 40863099)
261. Zoberi, I.; Bradbury, C.M.; Curry, H.A.; Bisht, K.S.; Goswami, P.C.; Roti Roti, J.L. and Gius, D. Radiosensitizing and anti-proliferative effects of resveratrol in two human cervical tumor cell lines. Cancer Lett., 2002, 175, 165-173. (Pubitemid 34001714)
262. Leone, S.; Fiore, M.; Lauro, M.G.; Pino, S.; Cornetta, T. and Cozzi, R. Resveratrol and X rays affect gap junction intercellular communications in human glioblastoma cells. Mol. Carcinog., 2008, 47, 587-598.
263. Scarlatti, F.; Sala, G.; Ricci, C.; Maioli, C.; Milani, F.; Minella, M.; Botturi, M. and Ghidoni, R. Resveratrol sensitization of DU145 prostate cancer cells to ionizing radiation is associated to ceramide increase. Cancer Lett., 2007, 253, 124-130. (Pubitemid 46874732)
264. Kao, C.L.; Huang, P.I.; Tsai, P.H.; Tsai, M.L.; Lo, J.F.; Lee, Y.Y.; Chen, Y.J.; Chen, Y.W. and Chiou, S.H. Resveratrol-induced apoptosis and increased radiosensitivity in CD133-positive cells derived from atypical teratoid/ rhabdoid tumor. Int. J. Radiat. Oncol. Biol. Phys., 2009, 74, 219-228.
265. Baatout, S.; Derradji, H.; Jacquet, P. and Mergeay, M. Increased radiation sensitivity of an eosinophilic cell line following treatment with epigallocatechin- gallate, resveratrol and curcuma. Int. J. Mol. Med., 2005, 15, 337-352.
266. Baatout, S.; Derradji, H.; Jacquet, P.; Ooms, D.; Michaux, A. and Mergeay, M. Enhanced radiation-induced apoptosis of cancer cell lines after treatment with resveratrol. Int. J. Mol. Med., 2004, 13, 895-902.
267. Mutoh, M.; Takahashi, M.; Fukuda, K.; Matsushima-Hibiya, Y.; Mutoh, H.; Sugimura, T. and Wakabayashi, K. Suppression of cyclooxygenase-2 promoter- dependent transcriptional activity in colon cancer cells by chemopreventive agents with a resorcin-type structure. Carcinogenesis, 2000, 21, 959-963. (Pubitemid 30265140)
268. O'Leary, K.A.; de Pascual-Tereasa, S.; Needs, P.W.; Bao, Y.P.; O'Brien, N.M. and Williamson, G. Effect of flavonoids and vitamin E on cyclooxygenase- 2 (COX-2) transcription. Mutat. Res., 2004, 551, 245-254. (Pubitemid 38833512)
269. MacCarrone, M.; Lorenzon, T.; Guerrieri, P. and Agro, A.F. Resveratrol prevents apoptosis in K562 cells by inhibiting lipoxygenase and cyclooxygenase activity. Eur. J. Biochem., 1999, 265, 27-34. (Pubitemid 29466009)
270. Pinto, M.C.; Garcia-Barrado, J.A. and Macias, P. Resveratrol is a potent inhibitor of the dioxygenase activity of lipoxygenase. J. Agric. Food Chem., 1999, 47, 4842-4846. (Pubitemid 30016906)
271. Borisova, I.G. and Budnitskaia, E.V. [In vitro radiation sensitivity of lipoxygenase systems]. Radiobiologiia, 1981, 21, 58-62. (Pubitemid 11150434)
272. Pyo, H.; Choy, H.; Amorino, G.P.; Kim, J.S.; Cao, Q.; Hercules, S.K. and DuBois, R.N. A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin. Cancer Res., 2001, 7, 2998-3005. (Pubitemid 32963816)
273. Russo, S.M.; Tepper, J.E.; Baldwin, A.S., Jr.; Liu, R.; Adams, J.; Elliott, P. and Cusack, J.C., Jr. Enhancement of radiosensitivity by proteasome inhibition: Implications for a role of NF-kappaB. Int. J. Radiat. Oncol. Biol. Phys., 2001, 50, 183-193.
274. Chen, X.; Shen, B.; Xia, L.; Khaletzkiy, A.; Chu, D.; Wong, J.Y. and Li, J.J. Activation of nuclear factor kappaB in radioresistance of TP53-inactive human keratinocytes. Cancer Res., 2002, 62, 1213-1221. (Pubitemid 34160311)
275. Terakado, N.; Shintani, S.; Yano, J.; Chunnan, L.; Mihara, M.; Nakashiro, K. and Hamakawa, H. Overexpression of cyclooxygenase-2 is associated with radioresistance in oral squamous cell carcinoma. Oral. Oncol., 2004, 40, 383-389. (Pubitemid 38221385)
276. Lu, K.H.; Chen, Y.W.; Tsai, P.H.; Tsai, M.L.; Lee, Y.Y.; Chiang, C.Y.; Kao, C.L.; Chiou, S.H.; Ku, H.H.; Lin, C.H. and Chen, Y.J. Evaluation of radiotherapy effect in resveratrol-treated medulloblastoma cancer stem-like cells. Childs Nerv. Syst., 2009, 25, 543-550.
277. Fulda, S. and Debatin, K.M. Resveratrol-mediated sensitisation to TRAILinduced apoptosis depends on death receptor and mitochondrial signalling. Eur. J. Cancer, 2005, 41, 786-798. (Pubitemid 40342561)
278. Hollman, P.C.; van Trijp, J.M.; Buysman, M.N.; van der Gaag, M.S.; Mengelers, M.J.; de Vries, J.H. and Katan, M.B. Relative bioavailability of the antioxidant flavonoid quercetin from various foods in man. FEBS Lett., 1997, 418, 152-156. (Pubitemid 27514436)
279. Lee, M.J.; Wang, Z.Y.; Li, H.; Chen, L.; Sun, Y.; Gobbo, S.; Balentine, D.A. and Yang, C.S. Analysis of plasma and urinary tea polyphenols in human subjects. Cancer Epidemiol. Biomarkers Prev., 1995, 4, 393-399.
280. Xu, X.; Wang, H.J.; Murphy, P.A.; Cook, L. and Hendrich, S. Daidzein is a more bioavailable soymilk isoflavone than is genistein in adult women. J. Nutr., 1994, 124, 825-832. (Pubitemid 24200587)
281. Gescher, A.J. and Steward, W.P. Relationship between mechanisms, bioavailibility, and preclinical chemopreventive efficacy of resveratrol: A conundrum. Cancer Epidemiol. Biomarkers Prev., 2003, 12, 953-957. (Pubitemid 37310248)
282. Bertelli, A.; Bertelli, A.A.; Gozzini, A. and Giovannini, L. Plasma and tissue resveratrol concentrations and pharmacological activity. Drugs Exp. Clin. Res., 1998, 24, 133-138. (Pubitemid 28499568)
283. Lancon, A.; Hanet, N.; Jannin, B.; Delmas, D.; Heydel, J.M.; Lizard, G.; Chagnon, M.C.; Artur, Y. and Latruffe, N. Resveratrol in human hepatoma HepG2 cells: Metabolism and inducibility of detoxifying enzymes. Drug Metab. Dispos., 2007, 35, 699-703. (Pubitemid 46641555)
284. Wenzel, E.; Soldo, T.; Erbersdobler, H. and Somoza, V. Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats. Mol. Nutr. Food Res., 2005, 49, 482-494. (Pubitemid 40780395)
285. Wenzel, E. and Somoza, V. Metabolism and bioavailability of transresveratrol. Mol. Nutr. Food Res., 2005, 49, 472-481.
286. Boocock, D.J.; Faust, G.E.; Patel, K.R.; Schinas, A.M.; Brown, V.A.; Ducharme, M.P.; Booth, T.D.; Crowell, J.A.; Perloff, M.; Gescher, A.J.; Steward, W.P. and Brenner, D.E. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol. Biomarkers Prev., 2007, 16, 1246-1252. (Pubitemid 46984966)
287. Brown, V.A.; Patel, K.R.; Viskaduraki, M.; Crowell, J.A.; Perloff, M.; Booth, T.D.; Vasilinin, G.; Sen, A.; Schinas, A.M.; Piccirilli, G.; Brown, K.; Steward, W.P.; Gescher, A.J. and Brenner, D.E. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: Safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res., 2010, 70, 9003-9011.
288. Walle, T.; Hsieh, F.; DeLegge, M.H.; Oatis, J.E., Jr. and Walle, U.K. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos., 2004, 32, 1377-1382. (Pubitemid 39564557)
289. Almeida, L.; Vaz-da-Silva, M.; Falcao, A.; Soares, E.; Costa, R.; Loureiro, A.I.; Fernandes-Lopes, C.; Rocha, J.F.; Nunes, T.; Wright, L. and Soares-da- Silva, P. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol. Nutr. Food Res., 2009, 53, S7-15.
290. Nunes, T.; Almeida, L.; Rocha, J.F.; Falcao, A.; Fernandes-Lopes, C.; Loureiro, A.I.; Wright, L.; Vaz-da-Silva, M. and Soares-da-Silva, P. Pharmacokinetics of trans-resveratrol following repeated administration in healthy elderly and young subjects. J. Clin. Pharmacol., 2009, 49, 1477-1482.
291. Patel, K.R.; Brown, V.A.; Jones, D.J.; Britton, R.G.; Hemingway, D.; Miller, A.S.; West, K.P.; Booth, T.D.; Perloff, M.; Crowell, J.A.; Brenner, D.E.; Steward, W.P.; Gescher, A.J. and Brown, K. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res., 2010, 70, 7392-7399.
292. Baur, J.A. and Sinclair, D.A. Therapeutic potential of resveratrol: The in vivo evidence. Nat. Rev. Drug Discov., 2006, 5, 493-506. (Pubitemid 44136961)
293. de Santi, C.; Pietrabissa, A.; Mosca, F. and Pacifici, G.M. Glucuronidation of resveratrol, a natural product present in grape and wine, in the human liver. Xenobiotica, 2000, 30, 1047-1054. (Pubitemid 32099176)
294. De Santi, C.; Pietrabissa, A.; Spisni, R.; Mosca, F. and Pacifici, G.M. Sulphation of resveratrol, a natural compound present in wine, and its inhibition by natural flavonoids. Xenobiotica, 2000, 30, 857-866.
295. De Santi, C.; Pietrabissa, A.; Spisni, R.; Mosca, F. and Pacifici, G.M. Sulphation of resveratrol, a natural product present in grapes and wine, in the human liver and duodenum. Xenobiotica, 2000, 30, 609-617. (Pubitemid 30449570)
296. Schlachterman, A.; Valle, F.; Wall, K.M.; Azios, N.G.; Castillo, L.; Morell, L.; Washington, A.V.; Cubano, L.A. and Dharmawardhane, S.F. Combined resveratrol, quercetin, and catechin treatment reduces breast tumor growth in a nude mouse model. Transl. Oncol., 2008, 1, 19-27.
297. Bourassa, P.; Kanakis, C.D.; Tarantilis, P.; Pollissiou, M.G. and Tajmir- Riahi, H.A. Resveratrol, genistein, and curcumin bind bovine serum albumin. J. Phys. Chem. B, 2010, 114, 3348-3354.
298. Lu, Z.; Zhang, Y.; Liu, H.; Yuan, J.; Zheng, Z. and Zou, G. Transport of a Cancer Chemopreventive Polyphenol, Resveratrol: Interaction with Serum Albumin and Hemoglobin. J. Fluoresc., 2007, 17, 580-587. (Pubitemid 47310330)
299. Lancon, A.; Delmas, D.; Osman, H.; Thenot, J.P.; Jannin, B. and Latruffe, N. Human hepatic cell uptake of resveratrol: Involvement of both passive diffusion and carrier-mediated process. Biochem. Biophys. Res. Commun., 2004, 316, 1132-1137. (Pubitemid 38369070)
300. Tsuji, P.A. and Walle, T. Benzo [a]pyrene-induced cytochrome P450 1A and DNA binding in cultured trout hepatocytes-Inhibition by plant polyphenols. Chem. Biol. Interact., 2007, 169, 25-31. (Pubitemid 47042707)
301. Berge, G.; Ovrebo, S.; Botnen, I.V.; Hewer, A.; Phillips, D.H.; Haugen, A. and Mollerup, S. Resveratrol inhibits benzo [a]pyrene-DNA adduct formation in human bronchial epithelial cells. Br. J. Cancer, 2004, 91, 333-338. (Pubitemid 39037080)
302. Frotschl, R.; Chichmanov, L.; Kleeberg, U.; Hildebrandt, A.G.; Roots, I. and Brockmoller, J. Prediction of aryl hydrocarbon receptor-mediated enzyme induction of drugs and chemicals by mRNA quantification. Chem. Res. Toxicol., 1998, 11, 1447-1452. (Pubitemid 29013617)
303. Le Ferrec, E.; Lagadic-Gossmann, D.; Rauch, C.; Bardiau, C.; Maheo, K.; Massiere, F.; Le Vee, M.; Guillouzo, A. and Morel, F. Transcriptional induction of CYP1A1 by oltipraz in human Caco-2 cells is aryl hydrocarbon receptor- and calcium-dependent. J. Biol. Chem., 2002, 277, 24780-24787. (Pubitemid 34952010)
304. Upadhyay, G.; Singh, A.K.; Kumar, A.; Prakash, O. and Singh, M.P. Resveratrol modulates pyrogallol-induced changes in hepatic toxicity markers, xenobiotic metabolizing enzymes and oxidative stress. Eur. J. Pharmacol., 2008, 596, 146-152.
305. Szaefer, H.; Cichocki, M.; Brauze, D. and Baer-Dubowska, W. Alteration in phase I and II enzyme activities and polycyclic aromatic hydrocarbons-DNA adduct formation by plant phenolics in mouse epidermis. Nutr. Cancer, 2004, 48, 70-77. (Pubitemid 38823548)
306. Hebbar, V.; Shen, G.; Hu, R.; Kim, B.R.; Chen, C.; Korytko, P.J.; Crowell, J.A.; Levine, B.S. and Kong, A.N. Toxicogenomics of resveratrol in rat liver. Life Sci., 2005, 76, 2299-2314. (Pubitemid 40313418)
307. Lu, J.; Ho, C.H.; Ghai, G. and Chen, K.Y. Resveratrol analog, 3,4,5,4'- tetrahydroxystilbene, differentially induces pro-apoptotic p53/Bax gene expression and inhibits the growth of transformed cells but not their normal counterparts. Carcinogenesis, 2001, 22, 321-328. (Pubitemid 32175522)
308. Zhang, S.; Cao, H.J.; Davis, F.B.; Tang, H.Y.; Davis, P.J. and Lin, H.Y. Oestrogen inhibits resveratrol-induced post-translational modification of p53 and apoptosis in breast cancer cells. Br. J. Cancer, 2004, 91, 178-185. (Pubitemid 39013062)